SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)

2/13/24 3:30:50 PM ET

Medical/Dental Instruments

Health Care

Get the next $IART alert in real time by email

SC 13G/A 1 IART_123123.txt CHAMPLAIN 13G TICKER IART UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ________)* INTEGRA LIFESCIENCES HOLDINGS CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457985208 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. 13G CUSIP No. 457985208 1. Names of Reporting Persons. Champlain Investment Partners, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] 3. SEC Use Only 4. Source of Funds (See Instructions) 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [ ] 6. Citizenship or Place of Organization Vermont Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 1800092 8. Shared Voting Power 9. Sole Dispositive Power 2435957 10. Shared Dispositive Power 11. Aggregate Amount Beneficially Owned by Each Reporting Person 2435957 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] 13. Percent of Class Represented by Amount in Row (11) 3.12% 14. Type of Reporting Person (See Instructions) IA 13G CUSIP No. 457985208 ITEM 1. (a) Name of Issuer: INTEGRA LIFESCIENCES HOLDINGS CORP (b) Address of Issuer's Principal Executive Offices: 1100 CAMPUS ROAD PRINCETON, NEW JERSEY 08540 ITEM 2. (a) Name of Person Filing: Champlain Investment Partners, LLC (b) Address of Principal Business Office, or if None, Residence: 180 Battery St., Burlington, Vermont 05401 (c) Citizenship: Vermont (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 457985208 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [_] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a- 8). (e) [x] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a- 3); (j) [_] Group, in accordance with ss.240.13d- 1(b)(1)(ii)(J). ITEM 4. OWNERSHIP. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 2435957 (b) Percent of class: 3.12% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 1800092 (ii) Shared power to vote or to direct the vote (iii) Sole power to dispose or to direct the disposition of 2435957 (iv) Shared power to dispose or to direct the disposition of INSTRUCTION. For computations regarding securities which represent a right to acquire an underlying security SEE ss.240.13d3(d)(1). ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. INSTRUCTION: Dissolution of a group requires a response to this item. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. If a group has filed this schedule pursuant to ss.240.13d- 1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group. ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. ITEM 10. CERTIFICATIONS. (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 2/13/2024 Signature: Matthew Garcia Name/Title: Matthew Garcia / Chief Compliance Officer The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties for whom copies are to be sent. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Get the next $IART alert in real time by email

Recent Analyst Ratings for

$IART

Date	Price Target	Rating	Analyst
3/31/2025		Hold → Buy	Argus
12/2/2024	$25.00 → $20.00	Underweight	Morgan Stanley
10/7/2024		Sell → Neutral	BTIG Research
7/30/2024	$22.00	Neutral → Sell	BTIG Research
7/30/2024	$30.00 → $23.00	Neutral → Sell	Citigroup
5/7/2024		Outperform → Perform	Oppenheimer
5/7/2024	$45.00 → $25.00	Overweight → Equal Weight	Wells Fargo
4/3/2024	$38.00	Sell → Neutral	Citigroup

More analyst ratings

SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $IART

$IART Financials

Live finance-specific insights

Integra LifeSciences Reports First Quarter 2025 Financial Results

Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance

$IART Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Integra upgraded by Argus

Morgan Stanley initiated coverage on Integra with a new price target

Integra upgraded by BTIG Research

$IART Press Releases

Fastest customizable press release news feed in the world

Integra LifeSciences Reports First Quarter 2025 Financial Results

Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

$IART Large Ownership Changes

This live feed shows all institutional transactions in real time.

$IART Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$IART Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$IART SEC Filings

SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

EVP, Chief Legal Officer & Sec Schwartz Eric covered exercise/tax liability with 2,718 shares, decreasing direct ownership by 5% to 56,020 units (SEC Form 4)

EVP & CHIEF FINANCIAL OFFICER Knight Lea Daniels covered exercise/tax liability with 1,655 shares and was granted 20,859 shares, increasing direct ownership by 46% to 61,139 units (SEC Form 4)

SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 443 shares and was granted 5,514 shares, increasing direct ownership by 14% to 40,882 units (SEC Form 4)

SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation

SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IART Leadership Updates

Live Leadership Updates

Jan De Witte joins GHO Capital as Operating Partner

Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Recent Analyst Ratings for
$IART

$IART
Financials

$IART
Analyst Ratings

$IART
Press Releases

$IART
Large Ownership Changes

$IART
Insider Purchases

$IART
Insider Trading

$IART
SEC Filings

$IART
Leadership Updates